← All trials
NCT05008575
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2021
- Primary completion
- Sep 1, 2022
- Completion date
- Sep 1, 2023
- First posted
- Aug 17, 2021
- Last posted
- Aug 17, 2021
- Enrollment
- 27
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- People's Liberation Army of ChinaLead sponsor
- People's Liberation Army of ChinaReponsible party - principal investigator
- Xinqiao Hospital of ChongqingOverall official - principal investigator
- Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.